Single compartment drug delivery

Journal of Controlled Release

Volumn 190, Issue , 2014, Pages 157-171

  Cima, Michael J ^a,b   Lee, Heejin ^c   Daniel, Karen ^c   Tanenbaum, Laura M ^a   Mantzavinou, Aikaterini ^a   Spencer, Kevin C ^a,b   Ong, Qunya ^a   Sy, Jay C ^a   Santini, John ^c   Schoellhammer, Carl M ^b   Blankschtein, Daniel ^b   Langer, Robert S ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c On Demand Therapeutics Inc ^*  (United States)

Author keywords

Controlled release drug delivery; Local therapy; Microfabrication; Noninvasive; Single compartment; Targeted therapy

Indexed keywords

DISEASE CONTROL; TARGETED DRUG DELIVERY; TISSUE; MICROFABRICATION;

CONTROLED RELEASE DRUG DELIVERY; CONTROLLED RELEASE DRUGS; DISEASED TISSUES; DRUG DESIGN; LOCAL THERAPY; MICRO-FABRICATION; MOLECULAR TARGETS; NONINVASIVE; SINGLE COMPARTMENT; TARGETED THERAPY;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; POLYMER; DELAYED RELEASE FORMULATION;

BLADDER; BLADDER PERMEABILITY; BLOOD BRAIN BARRIER; BRAIN; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONVECTION ENHANCED DELIVERY; DEPOT; DEVELOPMENTAL STAGE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; EYE; HUMAN; INDWELLING DEVICE; INTRACEREBRAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; LOCAL THERAPY; MEMBRANE DAMAGE; NEOPLASM; NONHUMAN; OPHTHALMOLOGICAL IMPLANT; OVARY CANCER; PERITONEAL CAVITY; PERITONEAL DISEASE; PERITONEUM; PERMEABILITY BARRIER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESERVOIR BASED DEVICE; REVIEW; SKIN; SUSTAINED DRUG RELEASE; SYSTEMIC THERAPY; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; UROLOGICAL THERAPEUTIC DEVICE; BODY FLUID COMPARTMENT; CHEMOTHERAPY; DRUG IMPLANT; DRUG METABOLISM; INDWELLING CATHETER; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; CATHETERIZATION; DELAYED RELEASE FORMULATION; DEVICES; DRUG DESIGN; MOLECULARLY TARGETED THERAPY;

ADMINISTRATION, INTRAVESICAL; CATHETERIZATION; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84906788158     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.04.049     Document Type: Review

References (203)

1. L. Brannon-Peppas, and J.O. Blanchette Nanoparticle and targeted systems for cancer therapy Adv. Drug Deliv. Rev. 56 2004 1649 1659 (Pubitemid 39177694)
2. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792 (Pubitemid 32222155)
3. M.Y. Fink, and J.E. Chipuk Survival of HER2-positive breast cancer cells: receptor signaling to apoptotic control centers Genes Cancer 4 2013 187 195
4. S. Minner, B. Jessen, L. Stiedenroth, E. Burandt, J. Kollermann, M. Mirlacher, A. Erbersdobler, C. Eichelberg, M. Fisch, T.H. Brummendorf, C. Bokemeyer, R. Simon, T. Steuber, M. Graefen, H. Huland, G. Sauter, and T. Schlomm Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer Clin. Cancer Res. 16 2010 1553 1560
5. D.L. Nielsen, M. Andersson, and C. Kamby HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors Cancer Treat. Rev. 35 2009 121 136
6. R. Nahta, D. Yu, M.C. Hung, G.N. Hortobagyi, and F.J. Esteva Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat. Clin. Pract. Oncol. 3 2006 269 280 (Pubitemid 43731112)
7. H. Korkaya, and M.S. Wicha HER-2, notch, and breast cancer stem cells: targeting an axis of evil Clin. Cancer Res. 15 2009 1845 1847
8. R.N. Dubois, S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, L.B. Van De Putte, and P.E. Lipsky Cyclooxygenase in biology and disease FASEB J. 12 1998 1063 1073 (Pubitemid 28418937)
9. N.J. Rothwell, and S.J. Hopkins Cytokines and the nervous system II: actions and mechanisms of action Trends Neurosci. 18 1995 130 136
10. M. Ek, D. Engblom, S. Saha, A. Blomqvist, P.J. Jakobsson, and A. Ericsson-Dahlstrand Inflammatory response: pathway across the blood-brain barrier Nature 410 2001 430 431 (Pubitemid 32240034)
11. J.L. Au, R.A. Badalament, M.G. Wientjes, D.C. Young, J.A. Warner, P.L. Venema, D.L. Pollifrone, J.D. Harbrecht, J.L. Chin, S.P. Lerner, B.J. Miles, and C.C. International Mitomycin Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial J. Natl. Cancer Inst. 93 2001 597 604 (Pubitemid 32409627)
12. Y.C. Ruan, W. Zhou, and H.C. Chan Regulation of smooth muscle contraction by the epithelium: role of prostaglandins Physiology 26 2011 156 170
13. N. Kvirkvelia, M. McMenamin, K. Chaudhary, M. Bartoli, and M.P. Madaio Prostaglandin E2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells Am. J. Physiol. Ren. Physiol. 304 2013 F463 F470
14. T. Liu, T.M. Laidlaw, H.R. Katz, and J.A. Boyce Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes Proc. Natl. Acad. Sci. U. S. A. 110 2013 16987 16992
15. S. Philipose, V. Konya, I. Sreckovic, G. Marsche, I.T. Lippe, B.A. Peskar, A. Heinemann, and R. Schuligoi The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation Arterioscler. Thromb. Vasc. Biol. 30 2010 2416 2423
16. C. Palileo, and J.D. Kaunitz Gastrointestinal defense mechanisms Curr. Opin. Gastroenterol. 27 2011 543 548
17. D.L. Simmons Variants of cyclooxygenase-1 and their roles in medicine Thromb. Res. 110 2003 265 268 (Pubitemid 37329823)
18. K. Seibert, Y. Zhang, K. Leahy, S. Hauser, J. Masferrer, W. Perkins, L. Lee, and P. Isakson Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain Proc. Natl. Acad. Sci. U. S. A. 91 1994 12013 12017 (Pubitemid 24368594)
19. C. Waskewich, R.D. Blumenthal, H. Li, R. Stein, D.M. Goldenberg, and J. Burton Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines Cancer Res. 62 2002 2029 2033 (Pubitemid 34408448)
20. W.G. Bensen, S.Z. Zhao, T.A. Burke, R.A. Zabinski, R.W. Makuch, C.J. Maurath, N.M. Agrawal, and G.S. Geis Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo J. Rheumatol. 27 2000 1876 1883
21. J.L. Goldstein, F.E. Silverstein, N.M. Agrawal, R.C. Hubbard, J. Kaiser, C.J. Maurath, K.M. Verburg, and G.S. Geis Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor Am. J. Gastroenterol. 95 2000 1681 1690 (Pubitemid 30485002)
22. J.L. Goldstein Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib J. Rheumatol. Suppl. 60 2000 25 28
23. B. Caldwell, S. Aldington, M. Weatherall, P. Shirtcliffe, and R. Beasley Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis J. R. Soc. Med. 99 2006 132 140
24. S.P. Johnsen, H. Larsson, R.E. Tarone, J.K. McLaughlin, B. Norgard, S. Friis, and H.T. Sorensen Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study Arch. Intern. Med. 165 2005 978 984 (Pubitemid 40638117)
25. S.E. Kimmel, J.A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B.L. Strom Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction Ann. Intern. Med. 142 2005 157 164 (Pubitemid 40189107)
26. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N. Engl. J. Med. 345 2001 433 442 (Pubitemid 32747607)
27. C.R. Chapple Muscarinic receptor antagonists in the treatment of overactive bladder Urology 55 2000 33 46
28. G.G. Kay, M.B. Abou-Donia, W.S. Messer Jr., D.G. Murphy, J.W. Tsao, and J.G. Ouslander Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients J. Am. Geriatr. Soc. 53 2005 2195 2201 (Pubitemid 43001205)
29. K.-E. Andersson Antimuscarinics for treatment of overactive bladder Lancet Neurol 3 2004 46 53 (Pubitemid 38018927)
30. K. Glavind, and M. Chancellor Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity Int. Urogynecol. J. 22 2011 907 917
31. M.P. Caulfield Muscarinic receptors - characterization, coupling and function Pharmacol. Ther. 58 1993 319 379 (Pubitemid 23273186)
32. M. Yamada, T. Miyakawa, A. Duttaroy, A. Yamanaka, T. Moriguchi, R. Makita, M. Ogawa, C.J. Chou, B. Xia, and J.N. Crawley Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean Nature 410 2001 207 212 (Pubitemid 32216592)
33. C.R. Chapple, T. Yamanishi, and R. Chess-Williams Muscarinic receptor subtypes and management of the overactive bladder Urology 60 2002 82 88
34. C. Chapple, V. Khullar, Z. Gabriel, and J.A. Dooley The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis Eur. Urol. 48 2005 5 26 (Pubitemid 40835585)
35. C.R. Chapple, V. Khullar, Z. Gabriel, D. Muston, C.E. Bitoun, and D. Weinstein The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur. Urol. 54 2008 543 562
36. C.P. Nelson, P. Gupta, C.M. Napier, S.R. Nahorski, and R.A. Challiss Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland Pharmacol. Exp. Ther. 310 2004 1255 1265 (Pubitemid 39108948)
37. A. Gomelsky, and R.R. Dmochowski Antimuscarinic Drugs for Overactive Bladder 2012
38. D.E. Chung Topical pharmacotherapy for overactive bladder Curr. Bladder Dysfunct. Rep. 6 2011 20 24
39. A.W. Scott, B.M. Tyler, B.C. Masi, U.M. Upadhyay, Y.R. Patta, R. Grossman, L. Basaldella, R.S. Langer, H. Brem, and M.J. Cima Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model Biomaterials 32 2011 2532 2539
40. Y.C. Chuang, H.C. Kuo, and M.B. Chancellor Botulinum toxin for the lower urinary tract BJU Int. 105 2010 1046 1058
41. A. Mangera, A. Apostolidis, K.E. Andersson, P. Dasgupta, A. Giannantoni, C. Roehrborn, G. Novara, and C. Chapple An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders Eur. Urol. 2013
42. Y. Funahashi Editorial comment from Dr Funahashi to intravesical drug delivery for dysfunctional bladder Int. J. Urol. 20 2013 562 563
43. D. Zhang, P. Sun, P. Li, A. Xue, X. Zhang, H. Zhang, and X. Jin A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guerin in the treatment of bladder cancer Biomaterials 34 2013 10258 10266
44. E. McLarty, and C.B. Coker A novel device for reconstituting and delivering intravesical chemotherapy BJU Int. 91 2003 575 576 (Pubitemid 36570585)
45. A.H. Mostafid, R.G. Rajkumar, A.B. Stewart, and R. Singh Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer BJU Int. 97 2006 509 512
46. P. Krause, U. Fuhr, J. Schnitker, U. Albrecht, R. Stein, and P. Rubenwolf Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study J. Urol. 190 2013 1791 1797
47. S. GuhaSarkar, and R. Banerjee Intravesical drug delivery: challenges, current status, opportunities and novel strategies J. Control. Release 148 2010 147 159
48. C.C. Hsu, Y.C. Chuang, and M.B. Chancellor Intravesical drug delivery for dysfunctional bladder Int. J. Urol. 20 2013 552 562
49. P. Tyagi, P.C. Wu, M. Chancellor, N. Yoshimura, and L. Huang Recent advances in intravesical drug/gene delivery Mol. Pharm. 3 2006 369 379 (Pubitemid 44351919)
50. A. Giannantoni, S.M. Di Stasi, M.B. Chancellor, E. Costantini, and M. Porena New frontiers in intravesical therapies and drug delivery Eur. Urol. 50 2006 1183 1193 (discussion 1193) (Pubitemid 44692939)
51. P. Tyagi, S. Tyagi, J. Kaufman, L. Huang, and F. de Miguel Local drug delivery to bladder using technology innovations Urol. Clin. N. Am. 33 2006 519 530 (x) (Pubitemid 44444928)
52. S.M. Di Stasi, M. Valenti, C. Verri, E. Liberati, A. Giurioli, G. Leprini, F. Masedu, A.R. Ricci, F. Micali, and G. Vespasiani Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial Lancet Oncol. 12 2011 871 879
53. R.A. Owusu, M.R. Abern, and B.A. Inman Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer Biomed. Res. Int. 2013 2013 262313
54. R. Colombo, A. Salonia, Z. Leib, M. Pavone-Macaluso, and D. Engelstein Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC) BJU Int. 107 2011 912 918
55. P. Milla, C. Fiorito, F. Soria, S. Arpicco, L. Cattel, and P. Gontero Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients Cancer Chemother. Pharmacol. 2014
56. Y.C. Chuang, W.C. Lee, W.C. Lee, and P.H. Chiang Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome J. Urol. 182 2009 1393 1400
57. W.C. Lee, Y.C. Chuang, W.C. Lee, and P.H. Chiang Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome Kaohsiung J. Med. Sci. 27 2011 437 440
58. P. Tyagi, M.P. Kashyap, N. Kawamorita, T. Yoshizawa, M. Chancellor, and N. Yoshimura Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome ISRN Pharmacol. 2014 2014
59. K. Matsumoto, E. Kikuchi, M. Horinaga, T. Takeda, A. Miyajima, K. Nakagawa, and M. Oya Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model Hum. Gene Ther. 22 2011 1423 1432
60. J. Nirmal, P. Tyagi, M.B. Chancellor, J. Kaufman, M. Anthony, D.D. Chancellor, Y.T. Chen, and Y.C. Chuang Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure J. Urol. 189 2013 1553 1558
61. K. Men, W. Liu, L. Li, X. Duan, P. Wang, M. Gou, X. Wei, X. Gao, B. Wang, Y. Du, M. Huang, L. Chen, Z. Qian, and Y. Wei Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system Nanoscale 4 2012 6425 6433
62. D. Leopardo, S.C. Cecere, M. Di Napoli, C. Cavaliere, C. Pisano, S. Striano, L. Marra, L. Menna, L. Claudio, S. Perdona, S. Setola, M. Berretta, R. Franco, R. Tambaro, S. Pignata, and G. Facchini Intravesical chemo-immunotherapy in non muscle invasive bladder cancer Eur. Rev. Med. Pharmacol. Sci. 17 2013 2145 2158
63. T. Leakakos, C. Ji, G. Lawson, C. Peterson, and S. Goodwin Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers Cancer Chemother. Pharmacol. 51 2003 445 450 (Pubitemid 36791668)
64. A.M. Nowicka, A. Kowalczyk, A. Jarzebinska, M. Donten, P. Krysinski, Z. Stojek, E. Augustin, and Z. Mazerska Progress in targeting tumor cells by using drug-magnetic nanoparticles conjugate Biomacromolecules 14 2013 828 833
65. T. Lin, J. Wu, X. Zhao, H. Lian, A. Yuan, X. Tang, S. Zhao, H. Guo, and Y. Hu In situ floating hydrogel for intravesical delivery of adriamycin without blocking urinary tract J. Pharm. Sci. 2014
66. I.S. Tobias, H. Lee, G.C. Engelmayr Jr., D. Macaya, C.J. Bettinger, and M.J. Cima Zero-order controlled release of ciprofloxacin-HCl from a reservoir-based, bioresorbable and elastomeric device J. Control. Release 146 2010 356 362
67. W. Michaeli, I. Michaelis, J. Grosse, M. Von Walter, E. Wintermantel, and N. Laar Development of an active agent carrying Biodegradable implant for the intravesical therapy of the overactive bladder syndrome Society of Plastics Engineers ANTEC Conference; 67th 2009 2951 2956
68. M. Haupt, M. Thommes, A. Heidenreich, and J. Breitkreutz Lipid-based intravesical drug delivery systems with controlled release of trospium chloride for the urinary bladder J. Control. Release 170 2013 161 166
69. R.R. Dmochowski, and R.A. Appell Advancements in pharmacologic management of the overactive bladder Urology 56 2000 41 49
70. M.B. Chancellor Future trends in the treatment of urinary incontinence Rev. Urol. 3 Suppl. 1 2001 S27 S34
71. M.O. Fraser, J.P. Lavelle, M.S. Sacks, and M.B. Chancellor The future of bladder control - intravesical drug delivery, a pinch of pepper, and gene therapy Rev. Urol. 4 2002 1 11
72. Oxybutynin intravesical - situs I-oxy Drugs R&D 3 2002 82 83
73. H. Lee Drug Delivery Device for Bladder Disorders 2009 Massachusetts Institute of Technology
74. H. Lee, and M.J. Cima An intravesical device for the sustained delivery of lidocaine to the bladder J. Control. Release 149 2011 133 139
75. J.C. Nickel, P. Jain, N. Shore, J. Anderson, D. Giesing, H. Lee, G. Kim, K. Daniel, S. White, C. Larrivee-Elkins, J. Lekstrom-Himes, and M. Cima Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device Sci. Transl. Med. 4 2012 (43ra100)
76. M.J. Cima Microsystem technologies for medical applications Annu. Rev. Chem. Biomol. Eng. 2 2011 355 378
77. S. Herrlich, S. Spieth, S. Messner, and R. Zengerle Osmotic micropumps for drug delivery Adv. Drug Deliv. Rev. 64 2012 1617 1627
78. S. Payton Pain: novel lidocaine delivery device for chronic interstitial cystitis Nat. Rev. Urol. 9 2012 546
79. M.F. Flessner The transport barrier in intraperitoneal therapy Am. J. Physiol. Ren. Physiol. 288 2005 F433 F442
80. R.L. Dedrick, C.E. Myers, P.M. Bungay, and V.T. DeVita Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat. Rep. 62 1978 1 11 (Pubitemid 8278518)
81. S.B. Howell Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer Int. J. Gynecol. Cancer 18 Suppl. 1 2008 20 25 (Pubitemid 351389048)
82. C. Hasovits, and S. Clarke Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics Clin. Pharmacokinet. 51 2012 203 224
83. M. Markman Intraperitoneal antineoplastic drug delivery: rationale and results Lancet Oncol. 4 2003 277 283 (Pubitemid 36603295)
84. E. Lengyel Ovarian cancer development and metastasis Am. J. Pathol. 177 2010 1053 1064
85. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, J.A. Young, E.W. Franklin, D.L. Clarke-Pearson, V.K. Malviya, and B. DuBeshter Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N. Engl. J. Med. 335 1996 1950 1955 (Pubitemid 26428219)
86. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, L.F. Carson, S. Wadler, and J. Sickel Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J. Clin. Oncol. 19 2001 1001 1007 (Pubitemid 32176274)
87. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, L.J. Copeland, J.L. Walker, R.A. Burger, and G. Gynecologic Oncology Intraperitoneal cisplatin and paclitaxel in ovarian cancer N. Engl. J. Med. 354 2006 34 43 (Pubitemid 43048949)
88. D.K. Armstrong New issues in systemic therapy for ovarian cancer J. Natl. Compr. Cancer Netw. 11 2013 690 693
89. M. Cristea, E. Han, L. Salmon, and R.J. Morgan Practical considerations in ovarian cancer chemotherapy Ther. Adv. Med. Oncol. 2 2010 175 187
90. H. Naora, and D.J. Montell Ovarian cancer metastasis: integrating insights from disparate model organisms Nat. Rev. Cancer 5 2005 355 366 (Pubitemid 40637827)
91. Z. Lu, J. Wang, M.G. Wientjes, and J.L. Au Intraperitoneal therapy for peritoneal cancer Future Oncol. 6 2010 1625 1641
92. J.L. Walker, D.K. Armstrong, H.Q. Huang, J. Fowler, K. Webster, R.A. Burger, and D. Clarke-Pearson Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study Gynecol. Oncol. 100 2006 27 32 (Pubitemid 41815045)
93. M. Practice Committee of American Society for Reproductive Treatment of pelvic pain associated with endometriosis Fertil. Steril. 90 2008 S260 S269
94. D.R. Groothuis The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery Neuro-Oncology 2 2000 45 59
95. D.J. Zgaljardic, J.C. Borod, N.S. Foldi, and P. Mattis A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry Cogn. Behav. Neurol. 16 2003 193 210 (Pubitemid 37517825)
96. A.L. Brody, S. Saxena, P. Stoessel, L.A. Gillies, L.A. Fairbanks, S. Alborzian, M.E. Phelps, S.C. Huang, H.M. Wu, M.L. Ho, M.K. Ho, S.C. Au, K. Maidment, and L.R. Baxter Jr. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings Arch. Gen. Psychiatry 58 2001 631 640 (Pubitemid 32640857)
97. M.R. DeLong, and T. Wichmann Circuits and circuit disorders of the basal ganglia Arch. Neurol. 64 2007 20 24 (Pubitemid 46072419)
98. R. Marsh, T.V. Maia, and B.S. Peterson Functional disturbances within frontostriatal circuits across multiple childhood psychopathologies Am. J. Psychiatry 166 2009 664 674
99. K. Amemori, and A.M. Graybiel Localized microstimulation of primate pregenual cingulate cortex induces negative decision-making Nat. Neurosci. 15 2012 776 785
100. N.J. Abbott, and I.A. Romero Transporting therapeutics across the blood-brain barrier Mol. Med. Today 2 1996 106 113 (Pubitemid 126407728)
101. W.M. Pardridge Drug and gene targeting to the brain with molecular Trojan horses Nat. Rev. Drug Discov. 1 2002 131 139 (Pubitemid 41646520)
102. D.R. Groothuis, B.E. Lippitz, I. Fekete, K.E. Schlageter, P. Molnar, O.M. Colvin, C.R. Roe, D.D. Bigner, and H.S. Friedman The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma Cancer Res. 52 1992 5590 5596
103. E. Garcia-Garcia, K. Andrieux, S. Gil, and P. Couvreur Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298 2005 274 292 (Pubitemid 40910731)
104. M.I. Koukourakis, S. Koukouraki, I. Fezoulidis, N. Kelekis, G. Kyrias, S. Archimandritis, and N. Karkavitsas High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours Br. J. Cancer 83 2000 1281 1286
105. K. Fabel, J. Dietrich, P. Hau, C. Wismeth, B. Winner, S. Przywara, A. Steinbrecher, W. Ullrich, and U. Bogdahn Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin Cancer 92 2001 1936 1942 (Pubitemid 32952514)
106. S.I. Rapoport, and H.K. Thompson Osmotic opening of the blood-brain barrier in the monkey without associated neurological deficits Science 180 1973 971
107. H. Pajouhesh, and G.R. Lenz Medicinal chemical properties of successful central nervous system drugs NeuroRx 2 2005 541 553 (Pubitemid 41393264)
108. I. Martin Prediction of blood-brain barrier penetration: are we missing the point? Drug Discov. Today 9 2004 161 162 (Pubitemid 38199960)
109. S.G. Summerfield, A.J. Lucas, R.A. Porter, P. Jeffrey, R.N. Gunn, K.R. Read, A.J. Stevens, A.C. Metcalf, M.C. Osuna, P.J. Kilford, J. Passchier, and A.D. Ruffo Toward an improved prediction of human in vivo brain penetration Xenobiotica 38 2008 1518 1535
110. P. Jeffrey, and S.G. Summerfield Challenges for blood-brain barrier (BBB) screening Xenobiotica 37 2007 1135 1151 (Pubitemid 350041554)
111. N. Bodor, and P. Buchwald Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease Drug Discov. Today 7 2002 766 774 (Pubitemid 34828174)
112. N. Bodor, and P. Buchwald Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems Adv. Drug Deliv. Rev. 36 1999 229 254 (Pubitemid 29121974)
113. K.M. Giacomini, S.-M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, and K.M. Hillgren Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
114. W.M. Pardridge Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses Bioconjug. Chem. 19 2008 1327 1338 (Pubitemid 352032329)
115. B. Obermeier, R. Daneman, and R.M. Ransohoff Development, maintenance and disruption of the blood-brain barrier Nat. Med. 19 2013 1584 1596
116. S.J. Madsen, and H. Hirschberg Site-specific opening of the blood-brain barrier J. Biophotonics 3 2010 356 367
117. A. Mangiola, P. de Bonis, G. Maira, M. Balducci, G. Sica, G. Lama, L. Lauriola, and C. Anile Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme Cancer 113 2008 841 846
118. J. Perry, A. Chambers, K. Spithoff, and N. Laperriere Gliadel wafers in the treatment of malignant glioma: a systematic review Curr. Oncol. 14 2007 189 194
119. R.J. Tamargo, J.S. Myseros, J.I. Epstein, M.B. Yang, M. Chasin, and H. Brem Interstitial chemotherapy of the 9 L gliosarcoma: controlled release polymers for drug delivery in the brain Cancer Res. 53 1993 329 333 (Pubitemid 23031845)
120. E. Sykova, and C. Nicholson Diffusion in brain extracellular space Physiol. Rev. 88 2008 1277 1340
121. L.K. Fung, M. Shin, B. Tyler, H. Brem, and W.M. Saltzman Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1- nitrosourea in the rat brain Pharm. Res. 13 1996 671 682 (Pubitemid 26156217)
122. B.C. Masi, B.M. Tyler, H. Bow, R.T. Wicks, Y. Xue, H. Brem, R. Langer, and M.J. Cima Intracranial MEMS based temozolomide delivery in a 9 L rat gliosarcoma model Biomaterials 33 2012 5768 5775
123. W.M. Saltzman, and M.L. Radomsky Drugs released from polymers: diffusion and elimination in brain tissue Chem. Eng. Sci. 46 1991 2429 2444
124. R.H. Bobo, D.W. Laske, A. Akbasak, P.F. Morrison, R.L. Dedrick, and E.H. Oldfield Convection-enhanced delivery of macromolecules in the brain Proc. Natl. Acad. Sci. U. S. A. 91 1994 2076 2080 (Pubitemid 24092045)
125. D.S. Bidros, J.K. Liu, and M.A. Vogelbaum Future of convection-enhanced delivery in the treatment of brain tumors Future Oncol. 6 2010 117 125
126. W. Debinski, and S.B. Tatter Convection-enhanced delivery for the treatment of brain tumors Expert. Rev. Neurother. 9 2009 1519 1527
127. T. Kikuchi, R. Saito, S. Sugiyama, Y. Yamashita, T. Kumabe, M. Krauze, K. Bankiewicz, and T. Tominaga Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models J. Neurosurg. 109 2008 867 873
128. U.W. Thomale, B. Tyler, V.M. Renard, B. Dorfman, M. Guarnieri, H.E. Haberl, and G.I. Jallo Local chemotherapy in the rat brainstem with multiple catheters: a feasibility study Childs Nerv. Syst. 25 2009 21 28
129. R. Raghavan, M.L. Brady, M.I. Rodriguez-Ponce, A. Hartlep, C. Pedain, and J.H. Sampson Convection-enhanced delivery of therapeutics for brain disease, and its optimization Neurosurg. Focus. 20 2006 E12
130. P. Rohatgi, N.B. Langhals, D.R. Kipke, and P.G. Patil In vivo performance of a microelectrode neural probe with integrated drug delivery Neurosurg. Focus. 27 2009 E8
131. A. Boiardi, M. Bartolomei, A. Silvani, M. Eoli, A. Salmaggi, E. Lamperti, I. Milanesi, A. Botturi, P. Rocca, L. Bodei, G. Broggi, and G. Paganelli Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma J. Neuro-Oncol. 72 2005 125 131 (Pubitemid 40796462)
132. S. Voulgaris, M. Partheni, M. Karamouzis, P. Dimopoulos, N. Papadakis, and H.P. Kalofonos Intratumoral doxorubicin in patients with malignant brain gliomas Am. J. Clin. Oncol. 25 2002 60 64 (Pubitemid 34131031)
133. A. Boiardi, M. Eoli, A. Pozzi, A. Salmaggi, G. Broggi, and A. Silvani Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients Ital. J. Neurol. Sci. 20 1999 43 48 (Pubitemid 29198212)
134. P. Riva, G. Franceschi, N. Riva, M. Casi, M. Santimaria, and M. Adamo Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach Eur. J. Nucl. Med. 27 2000 601 609 (Pubitemid 30262628)
135. R.A. Patchell, W.F. Regine, P. Ashton, P.A. Tibbs, D. Wilson, D. Shappley, and B. Young A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme J. Neuro-Oncol. 60 2002 37 42 (Pubitemid 35153532)
136. M.M. Patel, B.R. Goyal, S.V. Bhadada, J.S. Bhatt, and A.F. Amin Getting into the brain: approaches to enhance brain drug delivery CNS Drugs 23 2009 35 58
137. M.F. Salvatore, Y. Ai, B. Fischer, A.M. Zhang, R.C. Grondin, Z. Zhang, G.A. Gerhardt, and D.M. Gash Point source concentration of GDNF may explain failure of phase II clinical trial Exp. Neurol. 202 2006 497 505 (Pubitemid 44692690)
138. L. Xie, H. Kang, Q. Xu, M.J. Chen, Y. Liao, M. Thiyagarajan, J. O'Donnell, D.J. Christensen, C. Nicholson, J.J. Iliff, T. Takano, R. Deane, and M. Nedergaard Sleep drives metabolite clearance from the adult brain Science 342 2013 373 377
139. J.J. Iliff, M. Wang, Y. Liao, B.A. Plogg, W. Peng, G.A. Gundersen, H. Benveniste, G.E. Vates, R. Deane, and S.A. Goldman A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta Sci. Transl. Med. 4 2012 (147ra111)
140. C.E. Johanson, J.A. Duncan III, P.M. Klinge, T. Brinker, E.G. Stopa, and G.D. Silverberg Multiplicity of cerebrospinal fluid functions: new challenges in health and disease Cerebrospinal Fluid Res. 5 2008 10
141. D.D. Shen, A.A. Artru, and K.K. Adkison Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics Adv. Drug Deliv. Rev. 56 2004 1825 1857 (Pubitemid 39307054)
142. R.W. Sirianni, M.-Q. Zheng, W.M. Saltzman, Y. Huang, and R.E. Carson Direct, quantitative, and noninvasive imaging of the transport of active agents through intact brain with positron emission tomography Mol. Imaging Biol. 2013 1 10
143. T.L. Roth, D. Nayak, T. Atanasijevic, A.P. Koretsky, L.L. Latour, and D.B. McGavern Transcranial amelioration of inflammation and cell death after brain injury Nature 505 2014 223 228
144. M.S. Lesniak, and H. Brem Targeted therapy for brain tumours Nat. Rev. Drug Discov. 3 2004 499 508 (Pubitemid 38807532)
145. Y.K. Choi, and K.W. Kim Blood-neural barrier: its diversity and coordinated cell-to-cell communication BMB Rep. 41 2008 345 352
146. J.W. Streilein Ocular immune privilege: therapeutic opportunities from an experiment of nature Nat. Rev. Immunol. 3 2003 879 889 (Pubitemid 37411717)
147. S.S. Lee, and M.R. Robinson Novel drug delivery systems for retinal diseases. A review Ophthalmic Res. 41 2009 124 135
148. H.F. Edelhauser, C.L. Rowe-Rendleman, M.R. Robinson, D.G. Dawson, G.J. Chader, H.E. Grossniklaus, K.D. Rittenhouse, C.G. Wilson, D.A. Weber, B.D. Kuppermann, K.G. Csaky, T.W. Olsen, U.B. Kompella, V.M. Holers, G.S. Hageman, B.C. Gilger, P.A. Campochiaro, S.M. Whitcup, and W.T. Wong Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications Invest. Ophthalmol. Vis. Sci. 51 2010 5403 5420
149. Y.E. Choonara, V. Pillay, M.P. Danckwerts, T.R. Carmichael, and L.C. du Toit A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases J. Pharm. Sci. 99 2010 2219 2239
150. R. Gaudana, H.K. Ananthula, A. Parenky, and A.K. Mitra Ocular drug delivery AAPS J. 12 2010 348 360
151. Medicare Part B Physician/Supplier BESS Data for Calendar Year 2012, in.
152. S.R. Patel, D.E. Berezovsky, B.E. McCarey, V. Zarnitsyn, H.F. Edelhauser, and M.R. Prausnitz Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye Invest. Ophthalmol. Vis. Sci. 53 2012 4433 4441
153. B.C. Gilger, E.M. Abarca, J.H. Salmon, and S. Patel Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles Invest. Ophthalmol. Vis. Sci. 54 2013 2483 2492
154. R. Lo, P.Y. Li, S. Saati, R.N. Agrawal, M.S. Humayun, and E. Meng A passive MEMS drug delivery pump for treatment of ocular diseases Biomed. Microdevices 11 2009 959 970
155. P.-Y. Li, J. Shih, R. Lo, S. Saati, R. Agrawal, M.S. Humayun, Y.-C. Tai, and E. Meng An electrochemical intraocular drug delivery device Sensors Actuators A Phys. 143 2008 41 48 (Pubitemid 351417358)
156. F.N. Pirmoradi, J.K. Jackson, H.M. Burt, and M. Chiao On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device Lab Chip 11 2011 2744 2752
157. J.G. Souza, K. Dias, T.A. Pereira, D.S. Bernardi, and R.F. Lopez Topical delivery of ocular therapeutics: carrier systems and physical methods J. Pharm. Pharmacol. 2013
158. K.G. Csaky New developments in the transscleral delivery of ophthalmic agents Retin. Today 2007 32 35
159. M.A. Patane, A. Cohen, S. From, G. Torkildsen, D. Welch, and G.W. Ousler III Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial Clin. Ophthalmol. 5 2011 633 643
160. M. Nabili, H. Patel, S.P. Mahesh, J. Liu, C. Geist, and V. Zderic Ultrasound-enhanced delivery of antibiotics and anti-inflammatory drugs into the eye Ultrasound Med. Biol. 39 2013 638 646
161. W.L. Suen, H.S. Wong, Y. Yu, L.C. Lau, A.C. Lo, and Y. Chau Ultrasound-mediated transscleral delivery of macromolecules to the posterior segment of rabbit eye in vivo Invest. Ophthalmol. Vis. Sci. 54 2013 4358 4365
162. S.A. Molokhia, H. Sant, J. Simonis, C.J. Bishop, R.M. Burr, B.K. Gale, and B.K. Ambati The capsule drug device: novel approach for drug delivery to the eye Vis. Res. 50 2010 680 685
163. J. Lim, M. Wieland, A. Fung, D. Hung, and V. Wong A phase 1 study evaluating the safety and evidence of efficacy of IBI-20089, a triamcinolone intravitreal injection formulated with the VerisomeTM drug delivery technology, in patients with cystoid macular edema Invest. Ophthalmol. Vis. Sci. 50 2009 5395
164. pSivida, DURASERT™/LATANOPROST - pSivida www.psivida.com (in)
165. G.E. Sanborn, R. Anand, R.E. Torti, S.D. Nightingale, S.X. Cal, B. Yates, P. Ashton, and T. Smith Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device Arch. Ophthalmol. 110 1992 188 195
166. D.G. Callanan, G.J. Jaffe, D.F. Martin, P.A. Pearson, and T.L. Comstock Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results Arch. Ophthalmol. 126 2008 1191 1201
167. P.A. Campochiaro, D.M. Brown, A. Pearson, T. Ciulla, D. Boyer, F.G. Holz, M. Tolentino, A. Gupta, L. Duarte, S. Madreperla, J. Gonder, B. Kapik, K. Billman, F.E. Kane, and F.S. Group Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema Ophthalmology 118 2011 626 635 (e622)
168. P. Dugel, D. Eliott, H. Cantrill, T. Mahmoud, R. Avery, and S. Erickson I-Vation TA: 24-month clinical results of the phase I safety and preliminary efficacy study Proceedings of ARVO Annual Meeting 2009
169. J.A. Haller, F. Bandello, R. Belfort Jr., M.S. Blumenkranz, M. Gillies, J. Heier, A. Loewenstein, Y.H. Yoon, J. Jiao, X.Y. Li, S.M. Whitcup, G.S.G. Ozurdex, and J. Li Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results Ophthalmology 118 2011 2453 2460
170. C. Lowder, R. Belfort Jr., S. Lightman, C.S. Foster, M.R. Robinson, R.M. Schiffman, X.Y. Li, H. Cui, S.M. Whitcup, and H.S.G. Ozurdex Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis Arch. Ophthalmol. 129 2011 545 553
171. K. Kauper, C. McGovern, S. Sherman, P. Heatherton, R. Rapoza, P. Stabila, B. Dean, A. Lee, S. Borges, B. Bouchard, and W. Tao Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases Invest. Ophthalmol. Vis. Sci. 53 2012 7484 7491
172. C.L. Stevenson, J.T. Santini Jr., and R. Langer Reservoir-based drug delivery systems utilizing microtechnology Adv. Drug Deliv. Rev. 64 2012 1590 1602
173. R. Farra, N.F. Sheppard Jr., L. McCabe, R.M. Neer, J.M. Anderson, J.T. Santini Jr., M.J. Cima, and R. Langer First-in-human testing of a wirelessly controlled drug delivery microchip Sci. Transl. Med. 4 2012 (22ra121)
174. J.J. Escobar-Chavez, D. Bonilla-Martinez, M.A. Villegas-Gonzalez, E. Molina-Trinidad, N. Casas-Alancaster, and A.L. Revilla-Vazquez Microneedles: a valuable physical enhancer to increase transdermal drug delivery J. Clin. Pharmacol. 51 2011 964 977
175. R.K. Sivamani, B. Stoeber, G.C. Wu, H. Zhai, D. Liepmann, and H. Maibach Clinical microneedle injection of methyl nicotinate: stratum corneum penetration Skin Res. Technol. 11 2005 152 156 (Pubitemid 40542856)
176. J. Gupta, D.D. Denson, E.I. Felner, and M.R. Prausnitz Rapid local anesthesia in humans using minimally invasive microneedles Clin. J. Pain 28 2012 129 135
177. C. Sinico, and A.M. Fadda Vesicular carriers for dermal drug delivery Expert Opin. Drug Deliv. 6 2009 813 825
178. K.S. Paudel, M. Milewski, C.L. Swadley, N.K. Brogden, P. Ghosh, and A.L. Stinchcomb Challenges and opportunities in dermal/transdermal delivery Ther. Deliv. 1 2010 109 131
179. N.K. Brogden, S.L. Banks, L.J. Crofford, and A.L. Stinchcomb Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans Pharm. Res. 30 2013 1947 1955
180. J.D. Bos, and M.M. Meinardi The 500 Dalton rule for the skin penetration of chemical compounds and drugs Exp. Dermatol. 9 2000 165 169 (Pubitemid 30255378)
181. A.C. Williams, and B.W. Barry Penetration enhancers Adv. Drug Deliv. Rev. 56 2004 603 618 (Pubitemid 38326936)
182. C.M. Schoellhammer, D. Blankschtein, and R. Langer Skin permeabilization for transdermal drug delivery: recent advances and future prospects Expert Opin. Drug Deliv. 2014
183. A. Arora, E. Kisak, P. Karande, J. Newsam, and S. Mitragotri Multicomponent chemical enhancer formulations for transdermal drug delivery: more is not always better J. Control. Release 144 2010 175 180
184. M.N. Walter, K.T. Wright, H.R. Fuller, S. MacNeil, and W.E. Johnson Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays Exp. Cell Res. 316 2010 1271 1281
185. T. Gambichler, S. Boms, M. Stucker, A. Kreuter, G. Moussa, M. Sand, P. Altmeyer, and K. Hoffmann Epidermal thickness assessed by optical coherence tomography and routine histology: preliminary results of method comparison J. Eur. Acad. Dermatol. Venereol. 20 2006 791 795 (Pubitemid 44102910)
186. B.E. Polat, D. Hart, R. Langer, and D. Blankschtein Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends J. Control. Release 152 2011 330 348
187. B.E. Polat, D. Blankschtein, and R. Langer Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs Expert Opin. Drug Deliv. 7 2010 1415 1432
188. B.M. Becker, S. Helfrich, E. Baker, K. Lovgren, P.A. Minugh, and J.T. Machan Ultrasound with topical anesthetic rapidly decreases pain of intravenous cannulation Acad. Emerg. Med. 12 2005 289 295 (Pubitemid 40432298)
189. S. Mitragotri, and J. Kost Low-frequency sonophoresis: a review Adv. Drug Deliv. Rev. 56 2004 589 601 (Pubitemid 38326935)
190. D.V. McAllister, P.M. Wang, S.P. Davis, J.H. Park, P.J. Canatella, M.G. Allen, and M.R. Prausnitz Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies Proc. Natl. Acad. Sci. U. S. A. 100 2003 13755 13760 (Pubitemid 37499139)
191. S. Henry, D.V. McAllister, M.G. Allen, and M.R. Prausnitz Microfabricated microneedles: a novel approach to transdermal drug delivery J. Pharm. Sci. 88 1999 948
192. M.R. Prausnitz Microneedles for transdermal drug delivery Adv. Drug Deliv. Rev. 56 2004 581 587 (Pubitemid 38326934)
193. H.A. Benson Transdermal drug delivery: penetration enhancement techniques Curr. Drug Deliv. 2 2005 23 33 (Pubitemid 40590918)
194. B.W. Barry Novel mechanisms and devices to enable successful transdermal drug delivery Eur. J. Pharm. Sci. 14 2001 101 114 (Pubitemid 32737532)
195. H. Trommer, and R.H. Neubert Overcoming the stratum corneum: the modulation of skin penetration. A review Skin Pharmacol. Physiol. 19 2006 106 121 (Pubitemid 43725821)
196. R.H. Neubert Potentials of new nanocarriers for dermal and transdermal drug delivery Eur. J. Pharm. Biopharm. 77 2011 1 2
197. S. Mura, M. Manconi, C. Sinico, D. Valenti, and A.M. Fadda Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil Int. J. Pharm. 380 2009 72 79
198. M. Manconi, C. Sinico, C. Caddeo, A.O. Vila, D. Valenti, and A.M. Fadda Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin Int. J. Pharm. 412 2011 37 46
199. M.L. Manca, M. Manconi, A.M. Falchi, I. Castangia, D. Valenti, S. Lampis, and A.M. Fadda Close-packed vesicles for diclofenac skin delivery and fibroblast targeting Colloids Surf. B: Biointerfaces 111C 2013 609 617
200. J. Lademann, H. Richter, A. Teichmann, N. Otberg, U. Blume-Peytavi, J. Luengo, B. Weiss, U.F. Schaefer, C.M. Lehr, R. Wepf, and W. Sterry Nanoparticles - an efficient carrier for drug delivery into the hair follicles Eur. J. Pharm. Biopharm. 66 2007 159 164 (Pubitemid 46654773)
201. R. Toll, U. Jacobi, H. Richter, J. Lademann, H. Schaefer, and U. Blume-Peytavi Penetration profile of microspheres in follicular targeting of terminal hair follicles J. Investig. Dermatol. 123 2004 168 176 (Pubitemid 38833478)
202. M. Gupta, and S.P. Vyas Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis Chem. Phys. Lipids 165 2012 454 461
203. M. Crosera, M. Bovenzi, G. Maina, G. Adami, C. Zanette, C. Florio, and F. Filon Larese Nanoparticle dermal absorption and toxicity: a review of the literature Int. Arch. Occup. Environ. Health 82 2009 1043 1055